Sangamo Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Sangamo Therapeutics reports significant financial challenges, including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern, while advancing its neurology pipeline.
OTC.Pink
Sangamo Therapeutics reported a significant revenue decline and increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern, while also receiving a Nasdaq delisting extension.
OTC.Pink
Sangamo Therapeutics reports improved Q2 2025 financials driven by new collaborations but warns of substantial doubt about its ability to continue as a going concern.
OTC.Pink
Sangamo Therapeutics announces its Q1 2025 financial results, highlighting progress in neurology programs and ongoing efforts to secure additional funding amid going concern uncertainties.
OTC.Pink
10-Q: Sangamo Therapeutics Reports Q3 2024 Results, Highlights Genentech Deal and Fabry Program Progress
Sangamo Therapeutics announced its Q3 2024 financial results, emphasizing a significant collaboration with Genentech and a potential accelerated approval pathway for its Fabry disease program.
OTC.Pink
Sangamo Therapeutics reported its Q2 2024 results, highlighting a strategic focus on neurology and a new licensing agreement, while also acknowledging substantial doubt about its ability to continue as a going concern.
OTC.Pink
Sangamo Therapeutics reported its first quarter 2024 results, highlighting a significant decrease in revenue and ongoing restructuring efforts while facing substantial doubt about its ability to continue as a going concern.